Basecamp Mentoring

Begin your journey toward Engineering the Future of Medicine through Basecamp Mentoring

As part of our new freshman Science Foundations experience, students will meet in small groups with a mentor throughout their first year. This Basecamp Mentoring program is designed to get first-year students started on their Hopkins BME journey. In a series of discussion-based meetings each semester, mentors will share their unique perspectives on concepts related to course material and the broader world of biomedical engineering, including research applications, opportunities in the BME program, and more. These interactions will stimulate intellectual curiosity, provide a solid foundation for continued study at Hopkins BME, create lifelong bonds between students and both their peers and Hopkins faculty, and launch students on their path toward academic, professional, and personal success.

Learn more about our Basecamp mentors below.

Josh DoloffDr. Joshua C. Doloff is an assistant professor of biomedical engineering and materials science & engineering at Johns Hopkins University. He is also a faculty member of the Translational Tissue Engineering Center (TTEC).

Dr. Doloff earned his BSE in bioengineering from the University of Pennsylvania, and his PhD in molecular, cellular biology, and biochemistry from Boston University. His doctoral work on genetic engineering of cancer-targeted viral vectors won technology development and University Provost awards. This work, together with his research on chemotherapy-induced anti-tumor immune response, also earned him the Frank A. Belamarich Award for outstanding doctoral dissertation in his graduating class.

He then performed postdoctoral research as a Juvenile Diabetes Research Foundation (JDRF) Fellow in the labs of Drs. Robert Langer and Daniel G. Anderson at MIT, where he worked to understand and then prevent immune-mediated rejection of macroscale biomaterial and biomedical device implants. These efforts contributed to numerous publications, awarded or pending patents, and a new lab-founded startup company. While Josh has received multiple honors over the years, he was recently presented with a Distinguished Alumni Award from his doctoral department at Boston University.

In November 2018, Dr. Doloff became a new assistant professor of biomedical engineering and materials science at the Johns Hopkins University. His lab, located within TTEC on the medical campus, focuses on research in the areas of immunoengineering and regenerative medicine. He plans on utilizing systems and synthetic biology approaches to understand complex tissue dynamics and generate improved therapeutic platforms for multiple applications, including autoimmunity and transplantation medicine (ie, type 1 diabetes), ophthalmology, and cancer.
Warren GraysonDr. Warren Grayson is an associate professor of biomedical engineering and material sciences & engineering at Johns Hopkins University. He is also a founding member of the Translational Tissue Engineering Center (TTEC).

He obtained his BSc in chemical & process engineering from the University of the West Indies, his PhD in biomedical engineering from Florida State University, and completed his postdoctoral training at Columbia University in New York.

Dr. Grayson’s lab focuses on stem cell-based musculoskeletal tissue engineering. His lab studies the complex interactions that enable single cell populations to develop into functional composite tissues, employing unique modalities for activating specific pathways with spatial and temporal precision in order to coordinate the differentiation of stem cells. One of his main projects focuses on 3D-printing porous, biodegradable scaffolds and bioreactor design for personalized, craniofacial bone regeneration. Dr. Grayson’s laboratory is also currently studying how to regenerate functional skeletal muscle following volumetric tissue damage using advanced biomaterials and stem cells.
Dr. Jordan J. Green is a professor of biomedical engineering, ophthalmology, neurosurgery, oncology, chemical & biomolecular engineering, and materials science & engineering at the Johns Hopkins University School of Medicine. He is also co-founder and associate director of the Translational Tissue Engineering Center (TTEC), an associate researcher of the Institute for NanoBioTechnology (INBT), and director of the biomedical engineering undergraduate program at JHU.

Dr. Green received his BS in chemical engineering and in biomedical engineering from Carnegie Mellon University in 2003, and completed his PhD in biological engineering from the Massachusetts Institute of Technology in 2007. Subsequently, Dr. Green was a postdoctoral associate at MIT from 2007-2008.

Dr. Green is the CTO and co-founder of the Baltimore biotech company AsclepiX Therapeutics, a fellow of the American Institute for Medical and Biological Engineering, and an associate editor at Science Advances. His work has resulted in the publication of more than 100 scientific papers and 30 issued or pending patents. He has received numerous awards, including the American Institute of Chemical Engineers Allan Colburn Award, the Biomedical Engineering Society Rita Schaffer Award, the American Society for Engineering Education Curtis W. McGraw Research Award, the Presidential Early Career Award for Scientists and Engineers, and Popular Science’s Brilliant Ten. He is also a National Academy of Medicine Emerging Leader in Health & Medicine.

Dr. Green and his lab design and synthesize new biomaterials and particle systems that can deliver biologics such as peptides, proteins, nucleic acids, sugars, and small molecules specifically to various cell types, including cancer cells, immune cells, and stem cells. The lab is committed to the development of enabling nanobiotechnology as part of INBT, including the development of targeted anticancer therapeutics as part of the Sidney Kimmel Comprehensive Cancer Center, regenerative medicine cellular therapies as part of TTEC, immunotherapies as part of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, and ocular therapies as part of the Wilmer Eye Institute. Dr. Green and his lab are inventing the future of medicine through the innovation of advanced therapeutics.
Dr. Eileen Haase is an associate teaching professor in the Department of Biomedical Engineering at Johns Hopkins University.

She completed her master’s degree in electrical engineering from Johns Hopkins University while working at the Applied Physics Laboratory. She earned her PhD in biomedical engineering from Johns Hopkins University in the lab of Dr. Art Shoukas, focusing on the cardiovascular system and the control of blood pressure. Dr. Haase completed a postdoctoral fellowship with Dr. Lawrence Schramm, studying the neural control of the circulation. She was appointed as a lecturer in biomedical engineering in 2000 before becoming an associate teaching professor. Dr. Haase teaches high school students (through Engineering Innovations II), our BME undergraduates, and master’s degree students through the JHU Applied Biomedical Engineering program, which she chairs.

Dr. Haase has incorporated team-based learning and other active learning methods in many of the BME required courses. She is currently a Fulbright Scholar and visiting professor at Mbarara University of Science and Technology in Uganda, where she is using many of the best practices she developed at Johns Hopkins. Dr. Haase has a passion for teaching and has worked with JHU undergraduates on a number of technology fellowships to develop online resources that strengthen the BME undergraduate education. She was instrumental in developing the undergraduate Design Studio, and is continuously developing new challenges for our students.
Scot KuoDr. Scot Kuo is an associate professor of biomedical engineering and cell biology at the Johns Hopkins University. He is also the director of the Johns Hopkins School of Medicine Microscope Facility.

Growing up, Dr. Kuo has always been a ‘maker’, tinkering with digital electronics and computers as a young teenager. In college, his formal education included laboratory electronics and a machine shop course, but nothing substitutes for building with a real purpose. During a summer job with Dr. Veronica Vaida, then at Harvard, he designed and built a custom electronic timing interface that coordinated multiple instruments for pulsed-laser-spectroscopy of fast photochemical reactions. These skills have been invaluable in his later research.

Dr. Kuo earned his BA in biochemistry from Harvard University and his PhD in biochemistry with Dr. Daniel E. Koshland, Jr. at the University of California, Berkeley. He then completed his postdoctoral training with Dr. Michael P. Sheetz at Washington University in Saint Louis and at Duke University.

By developing new optical laser-based technologies using a multidisciplinary approach, Dr. Kuo’s research goal has been to understand the mechanical functions of cells. As a graduate student, he studied the swimming mechanics of bacteria as they sensed and responded to chemical gradients (chemotaxis); he used both molecular analysis of operon expression and video-tracking hardware/software that he built to analyze switching statistics of the flagellar motor complex. As a postdoctoral fellow, he used biochemical purification/reconstitution and laser tweezers that he built to achieve the first molecular-level force measurements of any biological molecule (the microtubule motor kinesin). As faculty, he has built other optical instruments, including laser-deflection particle-tracking microrheology, to understand reconstituted actin-based motility and mechanics of cultured animal cells. For example, laser-based nano-tracking within infected host cells led to the discovery of molecule-sized, step-like motions of the pathogen Listeria during actin-based motility, disproving prevailing Brownian ratchet models. His current projects include developing instrumentation and biochemical methodology for single-molecule (TIRF) and super-resolution (LLSM, SIM, STORM) imaging of cells and cell motility. As director of the School of Medicine Microscope Facility, he oversees advanced imaging equipment that includes seven high-end confocals, four super-resolution fluorescence microscopes, and three electron microscopes.
Elizabeth LogsdonDr. Elizabeth Logsdon is a senior lecturer and the associate director of academic programs in the Department of Biomedical Engineering at Johns Hopkins University. She is also co-director of the BME undergraduate Design Team program.

Dr. Logsdon earned a BS degree in chemical engineering at University of Virginia and continued her studies there, completing her PhD in biomedical engineering with Dr. Tom Skalak. Her work focused on how extracellular matrix adhesion regulates the differentiation of smooth muscle cells during development and tissue repair. Subsequently, she completed postdoctoral training in the Institute for Computational Medicine at Johns Hopkins, investigating decision-making processes of endothelial cells during angiogenesis, the growth of new blood vessels.

Her interdisciplinary training and interests led to her appointment as director of the Hopkins BME Design Studio and co-director of the BME Design Team program. The BME Design Studio is the nexus for design in the BME department, supporting the work of more than 500 students in projects ranging from tissue engineering to software development and medical device creation. Here, students learn by doing, tinkering, creating, and doing again. The BME Design Team program is our department’s oldest and most diverse design course sequence, dedicated to solving problems across the health system and biomedical industry. Student-led teams work shoulder-to-shoulder with Hopkins clinicians, expert faculty, and business professionals to develop meaningful solutions to real problems in healthcare. In this course, engineering excellence is matched with an understanding of regulatory affairs, intellectual property, and healthcare economics strategy to springboard translation of design solutions out of the classroom and into the clinic.
Feilim Mac GabhannDr. Feilim Mac Gabhann is an associate professor of biomedical engineering at Johns Hopkins University. He is also a faculty member of the Institute for Computational Medicine (ICM) and the Institute for NanoBioTechnology (INBT). He is also the director of the BME PhD program at Johns Hopkins.

Dr. Mac Gabhann received a BEng in chemical engineering from University College Dublin in Ireland; earned a PhD in biomedical engineering from Johns Hopkins University; and performed postdoctoral research at the University of Virginia. He has been a faculty member of Hopkins BME since 2009, and was appointed associate professor with tenure in 2016. Dr. Mac Gabhann has authored more than 60 peer-reviewed papers, and is co-editor-in-chief for the journal PLoS Computational Biology. He is also a Sloan Research Fellow and a recipient of a K99/R00 NIH Pathway to Independence Award, the August Krogh Young Investigator Award from the Microcirculatory Society, and the Arthur C. Guyton Award for Excellence in Integrative Physiology from the American Physiology Society. From Johns Hopkins, he has received a Catalyst award and the William H. Huggins Excellence in Teaching Award.

The Mac Gabhann lab uses computational models and systems pharmacology methods to design and optimize therapeutic approaches (drugs, gene therapy, cell therapy, and others) to combat diseases including peripheral artery disease, cancer, and HIV. The lab builds detailed computational models of the molecular and cellular mechanisms of disease, and uses them in different types of multiscale models: (a) whole-body pharmacokinetic/pharmacodynamic (PK/PD) models, incorporating multiple tissues with multiple cell types; and (b) high-resolution, image-based, 3D models of multicellular tissues. The lab also develops new data analysis techniques and applies both these and existing techniques to large datasets, with a particular emphasis on combining large datasets with detailed molecular-level models in order to simulate large populations of individuals and thereby run 'virtual clinical trials' of new and existing therapies.
Dr. Jamie Spangler is an assistant professor in biomedical engineering and chemical & biomolecular engineering at Johns Hopkins University.

She earned a BS degree in biomedical engineering at Johns Hopkins University and went on to conduct her PhD research in biological engineering in Dr. K. Dane Wittrup’s group at MIT, studying antibody-mediated down-regulation of epidermal growth factor receptor as a new mechanism for cancer therapy. She then completed a postdoctoral fellowship in Dr. K. Christopher Garcia’s lab in the molecular & cellular physiology and structural biology departments at Stanford University School of Medicine, focusing on engineering cytokine systems to bias immune homeostasis. She was appointed as an assistant professor at Johns Hopkins University in July 2017, jointly between the Departments of Biomedical Engineering and Chemical & Biomolecular Engineering.

The Spangler Lab is located in the Translational Tissue Engineering Center (TTEC) at the School of Medicine and is affiliated with the Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Immunotherapy. Dr. Spangler’s research group synthesizes cutting-edge tools and technologies from structural biology, protein engineering, and immunology to discover and design novel molecular therapeutics. Her lab is particularly interested in engineering immune proteins such as cytokines, growth factors, and antibodies for applications in cancer, infectious disease, and autoimmune disorder treatment. Building on the biophysical insights and new engineering platforms established by her group, Dr. Spangler is developing and pre-clinically evaluating new protein drugs that recruit new mechanisms to achieve targeted disease therapy.
Dr. Kristen Swaney is the scientific project administrator for the Department of Biomedical Engineering at Johns Hopkins.

Dr. Swaney earned her BS in biology, with minors in neuroscience and psychology, from Penn State University, and her PhD in biochemistry, cellular, and molecular biology from the Johns Hopkins University School of Medicine. She completed her thesis research with Dr. Peter Devreotes, focusing on cell signaling, polarity, and the actin cytoskeleton during cell migration. She then completed postdoctoral research with Dr. Rong Li, studying genomic instability and aneuploidy during cancer metastasis, as well as regulation of the immune response using in vivo and in vitro models of polycystic kidney disease. Her expertise includes advanced live cell microscopy, molecular biology, genetic engineering, cellular mechanics, biochemistry, and cell motility.

In addition to cell biology and genomics research, Dr. Swaney has a passion for writing and communications that began when she served as the editor of her high school newspaper. During her graduate and postdoctoral studies, she worked as a freelance science writer, composing and editing grants, manuscripts, science blogs, press releases, and more. She worked briefly for the science and corporate communications division of a health care and science policy consulting company before returning to Johns Hopkins in 2017. In her current role, Dr. Swaney oversees scientific and academic initiatives for the Department of Biomedical Engineering. She also directs marketing and communications, including the BME website, newsletters, marketing materials, and social media channels.
Katherine WilsonDr. Katherine L. Wilson is a professor of cell biology at the Johns Hopkins University School of Medicine.

Dr. Wilson grew up in the Pacific Northwest and earned her degree in microbiology as a college student at the University of Washington in Seattle. She earned her PhD in genetics at the University of California, San Francisco (UCSF), and was a Damon Runyon Walter Winchell postdoctoral fellow at the University of California, San Diego (UCSD), where she assembled functional 3D nuclei using extracts from frog eggs. She moved east to join the faculty in the Department of Cell Biology at the Johns Hopkins University School of Medicine.

She studies the cell nucleus— mothership of the human genome— focusing on three interdependent nuclear ‘lamina’ proteins named lamin A (LMNA), emerin (EMD) and Barrier-to-Autointegration Factor 1 (BANF1). Her lab uses biochemical, genetic and proteomic approaches to understand how mutations in these proteins cause tissue-specific disorders including muscular dystrophy, cardiomyopathy, type 2 diabetes, lipodystrophy, and progeria (‘accelerated aging’). Dr. Wilson has more than 100 peer-reviewed publications, and has presented her work at conferences around the world. She also teaches first-year medical and PhD students and is deeply invested in mentoring the next generation of diverse PhD scientists as director of the NIH-funded Hopkins PREP (Postbaccalaureate Research Education Program).
Raimond WinslowDr. Raimond L. Winslow is the Raj and Neera Singh Professor of Biomedical Engineering at Johns Hopkins University. He is the founding director of the Institute for Computational Medicine (ICM), vice chair of academic programs for the Department of Biomedical Engineering, and director of the BME master’s program.

Dr. Winslow grew up in Portland, Maine, and majored in electrical engineering as a college student at Worcester Polytechnic Institute in Worcester, Massachusetts. He earned his PhD in biomedical engineering at the Johns Hopkins University School of Medicine, and then moved to the Institute for Biomedical Computing at Washington University in St. Louis as a research associate. He returned to the faculty of the Johns Hopkins University School of Medicine in 1991.

He is recognized as the founder of the new field of computational medicine, which uses innovative computational models of the molecular biology, physiology, and anatomy of disease to understand, diagnose, and treat disease, and improve patient care. In his role at ICM, Dr. Winslow leads a collaborative team of engineers, mathematicians, computational scientists, and biomedical researchers from the Johns Hopkins University School of Medicine and the Whiting School of Engineering. ICM researchers develop a broad range of computational models of disease, personalize those models using data measured from the patient, and then apply them to diagnose and treat disease in a way that is tailored to the needs of the individual. His own research centers on cardiovascular system function in health and disease. He develops experimentally-based computational models and applies them to gain insights into the molecular basis of arrhythmias. Specifically, he studies computational modeling of intracellular signaling, metabolism, and electrical excitability in cardiac myocytes; biomedical data representation and database design; grid-computing and data-sharing; and integrative modeling of cardiac function in health and disease.
Dr. Kevin Yarema is an associate professor of biomedical engineering at Johns Hopkins University.

He earned BS degrees in biology and bioengineering at Walla Walla College (now Walla Walla University). He obtained a PhD from the Massachusetts Institute of Technology, studying platinum-based cancer drugs in Dr. John Essigmann’s lab. Dr. Yarema then completed a postdoctoral fellowship with Dr. Carolyn Bertozzi’s group at the University of California, Berkeley, where he helped develop “metabolic glycoengineering” technology. He joined Johns Hopkins in July 2001, and currently heads the Laboratory of Cell and Carbohydrate Engineering.

The Yarema Laboratory is located in the Translational Tissue Engineering Center (TTEC) at the Johns Hopkins School of Medicine. His research group first employs glycoengineering strategies to develop small-molecule carbohydrate-based drugs designed to treat cancer, arthritis, cardiovascular disorders, and other diseases. Secondly, they use their technology to improve the design and biomanufacturing of “biologics” – today’s preeminent class of new and emerging drugs that includes immunotherapeutics. Finally, they use metabolic glycoengineering to control stem cell fate, demonstrating the broad application of sugar-based intervention across biomedical disciplines ranging from conventional drug development, the design of emerging biologics, and regenerative medicine.